Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-23
2006-05-23
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S515000
Reexamination Certificate
active
07049335
ABSTRACT:
The subject invention provides a compound of the formula I,wherein X, Q, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10are as defined. Compounds of formula I have activity as opioid receptor antagonists. The subject invention furthermore provides for pharmaceutical compositions and therapeutic methods comprising compounds of formula I.
REFERENCES:
patent: 6313312 (2001-11-01), Banks et al.
patent: 6610711 (2003-08-01), Armer et al.
patent: 6812236 (2004-11-01), Gibson et al.
patent: 2002/0025948 (2002-02-01), Banks et al.
patent: 2002/0064825 (2002-05-01), Lewis et al.
patent: 2003/0013875 (2003-01-01), Banks et al.
patent: 2003/0087898 (2003-05-01), McHardy et al.
patent: 2003/0207876 (2003-11-01), Banks et al.
patent: 2004/0204445 (2004-10-01), Coe et al.
patent: 2004/0204453 (2004-10-01), McHardy et al.
patent: 2005/0043327 (2005-02-01), Coe et al.
patent: 2005/0075387 (2005-04-01), Tickner et al.
patent: 0506468 (1995-04-01), None
patent: 0506478 (1997-09-01), None
patent: 0287339 (2004-08-01), None
patent: WO 0039089 (2000-07-01), None
patent: WO 0198267 (2001-12-01), None
patent: WO 03 035622 (2003-05-01), None
patent: WO 03 101963 (2003-12-01), None
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet,URL:http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>.
U.S. Appl. No. 60/218,500.
Trayham, J.G. et al. “Effects of Ring Size on the Reactions of Cyclic Olefins Halohydrinsfrom Methylenecycloalkanes”Tetrahedron, Elsevier Science Publishers, vol. 7, 1959, pp. 165-172.
Beck, A., et al. “Preparation of Tetrahydrobenzodindoles from 1-Tetralones”, Jour. Chem. Society, Perkin Transactions 1, Letchworth GB, 1990, pp. 689-693.
Mosettig, E, et al. “Ring enlargement with diazomethane in the hydro-aromatic series”, Journ. Of American Chemical Society, vol. 52, 1930, pp. 3456-3463.
Talukdar, PB et al. “Chemistry of Ehtylenimine. VI. Pyrolysis of 7-acetyl-7azaspiro's 5.2loctane”, Journ Organic Chemistry, No. 24, 1959, pp. 526-528.
Piper J.R. “The use of alpha-amino acids in the synthesis of derivatives of 2-aminoethanethiol as potential antiradiaton agents” Jour. of Medicinal Chemistry, vol. 9, 1966, pp. 911-920.
Campbell, M.M., et al. “Spiroheterocylces derived from tetralone”, Tetrahedron, vol. 41, No. 23, 1985, pp. 5637-5644.
Mosettig, E, et al. “New alkamines in the tetrahydronapthalene series”, Journ. Of American Chemical Society, vol. 53, 1931, pp. 2295-2300.
Zhou, Z. et al.,Biophysical Journal. “Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature”, vol. 74, pp. 230-241 (1998).
Wilkinson, G.R.,New England Journal of Medicine, “Drug Metabolism and Variability Among Patients In Drug Response”, vol. 352, pp. 2211-2221 (2005).
Heck Steven D.
Liras Spiros
McHardy Stanton F.
Anderson Rebecca
Benson Gregg C.
Musser Arlene K.
Pfizer Inc.
Saeed Kamal A.
LandOfFree
3-azabicyclo[3.1.0]hexane derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-azabicyclo[3.1.0]hexane derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-azabicyclo[3.1.0]hexane derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3618866